HTR2A-AS1: A Potential Drug Target and Biomarker (G100874082)

Target Name: HTR2A-AS1

NCBI ID: G100874082

HTR2A-AS1

Other Name(s): HTR2A antisense RNA 1 | HTR2A antisense RNA 1, transcript variant 1

HTR2A-AS1: A Potential Drug Target and Biomarker

Human tissue factor receptor 2 (HTR2) is a transmembrane protein that plays a crucial role in the regulation of hemostasis, the process by which the body stops bleeding after injury or surgery. HTR2A-AS1 is a specific subunit of HTR2 that has been identified as a potential drug target and biomarker.

The HTR2A family consists of four subunits: HTR2A, HTR2B, HTR2C, and HTR2D. HTR2A-AS1 is a single chain of 214 amino acids that is expressed in various tissues, including platelets, endothelial cells, and smooth muscle cells. It has been shown to play a role in the regulation of platelet function and to be involved in the development of thromboembolic diseases.

HTR2A-AS1 has been shown to regulate the activity of several enzymes involved in platelet function, including the coagulation cascade. This suggests that it may be a good target for drugs that are designed to prevent or reverse thromboembolic events. Additionally, HTR2A-AS1 has been shown to play a role in the regulation of cell adhesion and migration, which may also be relevant to its function in thromboembolic disease.

As a potential drug target, HTR2A-AS1 could be targeted by small molecules or antibodies that can modulate its activity. For example, inhibitors of platelet aggregation could be used to prevent thromboembolic events by blocking the activity of HTR2A-AS1. Similarly, antibodies that recognize and segregate HTR2A-AS1 could be used to target it and potentially disrupt its function in thromboembolic disease.

HTR2A-AS1 is also a potential biomarker for thromboembolic disease. The expression of HTR2A-AS1 has been shown to be increased in individuals with genetic predisposition to thromboembolic disease, such as those with a history of venous thromboembolism or pulmonary embolism. Additionally, individuals with thromboembolic disease have been shown to have decreased levels of HTR2A-AS1 in their plasma compared to healthy individuals.

In conclusion, HTR2A-AS1 is a promising drug target and biomarker for thromboembolic disease. Its role in the regulation of platelet function and cell adhesion may make it an attractive target for small molecules or antibodies that can modulate its activity. Additionally, its potential as a biomarker for thromboembolic disease makes it an important area of research for the development of new treatments for this life-threatening condition.

Protein Name: HTR2A Antisense RNA 1

The "HTR2A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HTR2A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets